These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 34898019)

  • 1. A non-parametric approach for jointly combining evidence on progression free and overall survival time in network meta-analysis.
    Daly CH; Maconachie R; Ades AE; Welton NJ
    Res Synth Methods; 2022 Sep; 13(5):573-584. PubMed ID: 34898019
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Assessing surrogacy using restricted mean survival time ratio for overall survival in non-small cell lung cancer immunotherapy studies.
    Pang H; Yang G; Ho JC; Leung TH; Shi Q; Hu C; Stinchcombe TE; Wang X
    Chin Clin Oncol; 2022 Feb; 11(1):7. PubMed ID: 35255696
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Assessment of progression-free survival as a surrogate end-point for overall survival in patients with metastatic renal cell carcinoma.
    Négrier S; Bushmakin AG; Cappelleri JC; Korytowsky B; Sandin R; Charbonneau C; Michaelson MD; Figlin RA; Motzer RJ
    Eur J Cancer; 2014 Jul; 50(10):1766-1771. PubMed ID: 24768571
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Correlation of Milestone Restricted Mean Survival Time Ratio With Overall Survival Hazard Ratio in Randomized Clinical Trials of Immune Checkpoint Inhibitors: A Systematic Review and Meta-analysis.
    Wang ZX; Wu HX; Xie L; Wang YN; Yang LP; He MM; Luo HY; Ding PR; Xie D; Chen G; Li YH; Wang F; Xu RH
    JAMA Netw Open; 2019 May; 2(5):e193433. PubMed ID: 31050784
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Estimation of time to progression and post progression survival using joint modeling of summary level OS and PFS data with an ordinary differential equation model.
    Nagase M; Doshi S; Dutta S; Lin CW
    J Pharmacokinet Pharmacodyn; 2022 Aug; 49(4):455-469. PubMed ID: 35870059
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cabozantinib versus everolimus, nivolumab, axitinib, sorafenib and best supportive care: A network meta-analysis of progression-free survival and overall survival in second line treatment of advanced renal cell carcinoma.
    Amzal B; Fu S; Meng J; Lister J; Karcher H
    PLoS One; 2017; 12(9):e0184423. PubMed ID: 28886175
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparative efficacy and safety of licensed treatments for previously treated non-small cell lung cancer: A systematic review and network meta-analysis.
    Armoiry X; Tsertsvadze A; Connock M; Royle P; Melendez-Torres GJ; Souquet PJ; Clarke A
    PLoS One; 2018; 13(7):e0199575. PubMed ID: 30044785
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical Impact of Post-Progression Survival on Overall Survival in Elderly Patients with Non-Small-Cell Lung Cancer Harboring Sensitive EGFR Mutations Treated with First-Line EGFR Tyrosine Kinase Inhibitors.
    Imai H; Yamada Y; Sugiyama T; Minemura H; Kaira K; Kanazawa K; Kasai T; Kaburagi T; Minato K;
    Chemotherapy; 2018; 63(3):181-189. PubMed ID: 30107372
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bayesian multivariate network meta-analysis model for the difference in restricted mean survival times.
    Tang X; Trinquart L
    Stat Med; 2022 Feb; 41(3):595-611. PubMed ID: 34883534
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Relative efficacy of interventions in the treatment of second-line non-small cell lung cancer: a systematic review and network meta-analysis.
    Vickers AD; Winfree KB; Cuyun Carter G; Kiiskinen U; Jen MH; Stull D; Kaye JA; Carbone DP
    BMC Cancer; 2019 Apr; 19(1):353. PubMed ID: 30987609
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Post-Progression Survival Associated with Overall Survival in Patients with Advanced Non-Small-Cell Lung Cancer Receiving Docetaxel Monotherapy as Second-Line Chemotherapy.
    Kotake M; Miura Y; Imai H; Mori K; Sakurai R; Kaira K; Tomizawa Y; Minato K; Saito R; Hisada T
    Chemotherapy; 2017; 62(4):205-213. PubMed ID: 28380484
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Quantifying the Survival Benefits of Oncology Drugs With a Focus on Immunotherapy Using Restricted Mean Survival Time.
    Rahmadian AP; Delos Santos S; Parshad S; Everest L; Cheung MC; Chan KK
    J Natl Compr Canc Netw; 2020 Mar; 18(3):278-285. PubMed ID: 32135516
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical significance of post-progression survival in lung cancer.
    Imai H; Kaira K; Minato K
    Thorac Cancer; 2017 Sep; 8(5):379-386. PubMed ID: 28627767
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy of Tumor Vaccines and Cellular Immunotherapies in Non-Small-Cell Lung Cancer: A Systematic Review and Meta-Analysis.
    Dammeijer F; Lievense LA; Veerman GD; Hoogsteden HC; Hegmans JP; Arends LR; Aerts JG
    J Clin Oncol; 2016 Sep; 34(26):3204-12. PubMed ID: 27432922
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Progression-Free Survival Early Assessment Is a Robust Surrogate Endpoint of Overall Survival in Immunotherapy Trials of Hepatocellular Carcinoma.
    Cabibbo G; Celsa C; Enea M; Battaglia S; Rizzo GEM; Busacca A; Matranga D; Attanasio M; Reig M; Craxì A; Cammà C
    Cancers (Basel); 2020 Dec; 13(1):. PubMed ID: 33396833
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pembrolizumab for Previously Treated Advanced or Metastatic Urothelial Cancer: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
    Gallacher D; Armoiry X; Auguste P; Court R; Mantopoulos T; Patterson J; De Santis M; Cresswell J; Mistry H
    Pharmacoeconomics; 2019 Jan; 37(1):19-27. PubMed ID: 30030817
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Individual-level data on the relationships of progression-free survival, post-progression survival, and tumor response with overall survival in patients with advanced non-squamous non-small cell lung cancer.
    Imai H; Takahashi T; Mori K; Ono A; Akamatsu H; Shukuya T; Taira T; Kenmotsu H; Naito T; Murakami H; Endo M; Nakajima T; Yamamoto N
    Neoplasma; 2014; 61(2):233-40. PubMed ID: 24299320
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunotherapy in advanced kidney cancer: an alternative meta-analytic method using reconstructed survival data in case of proportional hazard assumption violation.
    Nocera L; Fallara G; Raggi D; Belladelli F; Robesti D; Montorsi F; Karakiewicz PI; Malavaud B; Ploussard G; Necchi A; Martini A
    Front Oncol; 2022; 12():955894. PubMed ID: 36132135
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Value of surgery for stage IIIa non-small cell lung cancer].
    Liu H; Wang M; Hu K; Xu Y; Ma M; Zhong W; Zhao J; Li L; Wang H
    Zhongguo Fei Ai Za Zhi; 2013 Dec; 16(12):639-45. PubMed ID: 24345488
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.